Bausch & Lomb eyes global options as it cuts staff
This article was originally published in Clinica
Executive Summary
Eye care company Bausch & Lomb is to cut 7% of its workforce by consolidating its contact lens manufacturing operations. It has highlighted other areas where further savings can be made and has also authorised the repurchase of five million shares. The value of B&L's shares rose by nearly 11% to $60.7 on the news, with a trading volume of nearly double the daily average.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.